Research progress on the effects of mineralocorticoid receptor on cardiovascular diseases

doi:10.16352/j.issn.1001-6325.2022.08.1292

Abstract

Abstract: The mineralocorticoid receptor (MR) is a ligand-activated cytoplasmic receptor.Activation of MR in different cells can cause cardiovascular inflammation, oxidative stress, tissue remodeling ,and even function change the activity of ion channels resulting in incidence of arrhythmia through various mechanisms.MR antagonists are effective medicine to treat hypertension,coronary heart disease,and heart failure. In addition, the role of MR in arrhythmia and pulmonary hypertension also provides new perspectives for future clinical medication.

Key words: mineralocorticoid receptor, cardiovascular disease, mechanism

CLC Number:

R365

MA Qian-yu, PENG Shi, ZHANG Zhao-yuan, ZHANG Dan, ZHANG Jin. Research progress on the effects of mineralocorticoid receptor on cardiovascular diseases[J]. Basic & Clinical Medicine, 2022, 42(8): 1292-1296.

References 25

[1]	Lu Q,Davel AP,Mcgraw AP,et al.PKCδ mediates mineralocorticoid receptor activation by angiotensin ii to modulate smooth muscle cell function[J].Endocrinology,2019,160:2101-2114.
[2]	Ong GSY,Young MJ.Mineralocorticoid regulation of cell function:the role of rapid signalling and gene transcrip-tion pathways[J].J Mol Endocrinol,2017,58:33-57.
[3]	González-Blázquez R,Somoza B,Gil-Ortega M,et al.Finerenone atenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress[J].Front Pharmacol,2018,9:1131-1144.
[4]	Shen JZ,Morgan J,Tesch GH,et al.Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages[J].Endocrinology,2016,157:3213-3223.
[5]	Moss ME,Lu Q,Iyer SL,et al.Endothelial mineralocor-ticoid receptors contribute to vascular inflammation in atherosclerosis in a sex-specific manner[J].Arterioscler Thromb Vasc Biol,2019,39:1588-1601.
[6]	Ferreira NS,Bruder-Nascimento T,Pereira CA,et al.NLRP3 inflammasome and mineralocorticoid receptors are associated with vascular dysfunction in type 2 diabetes mellitus[J].Cells,2019,8:1595-1608.
[7]	Zheng XJ,Liu Y,Zhang WC,et al.Mineralocorticoid receptor negatively regulates angiogenesis through repres-sion of STAT3 activity in endothelial cells[J].J Pathol,2019,248:438-451.
[8]	Kim SK,Mccurley AT,Dupont JJ,et al.Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging[J].Hypertension,2018,71:609-621.
[9]	Araos P,Prado C,Lozano M,et al.Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation[J].J Hypertens,2019,37:1482-1492.
[10]	Aroor AR,Habibi J,Nistala R,et al.Diet-induced obesity promotes kidney endothelial stiffening and fibrosis dependent on the endothelial mineralocorticoid receptor[J].Hypertension,2019,73:849-858.
[11]	Nakamura T,Kurihara I,Kobayashi S,et al.Intestinal mineralocorticoid receptor contributes to epithelial sodium channel-mediated intestinal sodium absorption and blood pressure regulation[J].J Am Heart Assoc,2018,7:e008259.doi:10.1161/JAHA.117.008259.
[12]	Ferreira JP,Rossignol P,Pizard A,et al.Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure[J].Heart,2019,105:307-314.
[13]	Ito S,Itoh H,Rakugi H,et al.Double-blind randomized phase 3 study comparing esaxerenone (cs-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)[J].Hypertension,2020,75:51-58.
[14]	Brown SM,Meuth AI,Davis JW,et al.Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction:a unique vascular transcriptomic signature[J].Pharmacol Res,2018,134:100-108.
[15]	Shen ZX,Chen XQ,Sun XN,et al.Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis[J].J Biol Chem,2017,292:925-935.
[16]	Fraccarollo D,Thomas S,Scholz CJ,et al.Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing[J].Hypertension,2019,73:102-111.
[17]	Kosmala W,Przewlocka-Kosmala M,Marwick TH.Association of active and passive components of lv diastolic filling with exercise intolerance in heart failure with preserved ejection fraction:mechanistic insights from spironolactone response[J].JACC Cardiovasc Imaging,2019,12:784-794.
[18]	Mcdiarmid AK,Swoboda PP,Erhayiem B,et al.Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction[J].J Am Heart Assoc,2020,9:e011521.doi:10.1161/JAHA.118.011521.
[19]	Serenelli M,Jackson A,Dewan P,et al.Mineralocorti-coid receptor antagonists,blood pressure,and outcomes in heart failure with reduced ejection fraction[J].JACC Heart Fail,2020,8:188-198.
[20]	Bienvenu LA,Morgan J,Reichelt ME,et al.Chronic in vivo nitric oxide deficiency impairs cardiac functional recovery after ischemia in female (but not male) mice[J].J Mol Cell Cardiol,2017,112:8-15.
[21]	Driessen HE,Fontes MS,Van Stuijvenberg L,et al.A combined CaMKII inhibition and mineralocorticoid recep-tor antagonism via eplerenone inhibits functional deterioration in chronic pressure overloaded mice[J].J Cell Mol Med,2020,24:8417-8429.
[22]	Yi Y,Du L,Qin M,et al.Regulation of atrial fibrosis by the bone[J].Hypertension,2019,73:379-389.
[23]	Wang Y,Zhong B,Wu Q,et al.Aldosterone contributed to pulmonary arterial hypertension development via stimulating aquaporin expression and pulmonary arterial smooth muscle cells proliferation[J].Pharmacology,2020,105:405-415.
[24]	Boehm M,Arnold N,Braithwaite A,et al.Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension[J].BMC Pulm Med,2018,18:41-58.
[25]	Elinoff JM,Chen LY,Dougherty EJ,et al.Spironolac-tone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling[J].Cardiovasc Res,2018,114:65-76.